XCUR vs FNGR Comparison

Exicure Inc is a clinical-stage biotechnology company focused on developing treatments for blood-related diseases, with an emphasis on small-molecule therapies that have the potential to benefit a broad range of patients. The company acquired GPCR Therapeutics USA and secured a license for GPC-100 (Burixafor), a clinical-stage small-molecule compound that inhibits the chemokine receptor CXCR4. GPC-100 has demonstrated the ability to effectively mobilize various cell types, including hematopoietic stem cells and lymphocytes, highlighting its broad therapeutic potential across multiple indications.

FingerMotion Inc is engaged in the provision of mobile payment and recharge services in the Chinese market. The Company organizes its operations across four primary areas: telecommunications products and services, marketplace platform and digital commerce infrastructure solutions, data and analytics platform solutions, and Advanced Technology And Platform Solutions. The company generates majority of revenue from telecommunications products and services segment. This segment includes mobile payment and recharge services, as well as enterprise messaging services such as short message services (SMS) and multimedia messaging services (MMS).